William C. Kisseberth

William C. Kisseberth

Auto-generated profile, based on publicly available information

William C. Kisseberth

Department of Veterinary Clinical Sciences, College of Veterinary Medicine The Ohio State University Columbus Ohio USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ALAmy K. LeBlanc
Amy K. LeBlanc
CMChristina N. Mazcko
Christina N. Mazcko
ACAswini Cherukuri
Aswini Cherukuri
EBErika P. Berger
Erika P. Berger
WKWilliam C. Kisseberth
William C. Kisseberth
TFTimothy Fan
Timothy Fan
Purpose: The mTOR pathway has been identified as a key nutrient signaling hub that participates in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is biologically achievable with sirolimus, and might slow the outgrowth of distant metastases. In this study, pet dogs with appendicular osteosarcoma were leveraged as high-value biologic models for pediatric osteosarcoma, to assess mTOR inhibition as a therapeutic strategy for attenuating metastatic disease progression. Patients and Methods: A total of 324 pet dogs diagnosed with treatment-naïve appendicular osteosarcoma were randomized into a two-arm, multicenter, parallel superiority trial whereby dogs received amputation of the affected limb, followed by adjuvant carboplatin chemotherapy ± oral sirolimus therapy. The primary outcome measure was disease-free interval (DFI), as assessed by serial physical and radiologic detection of emergent macroscopic metastases; secondary outcomes included overall 1- and 2-year survival rates, and sirolimus pharmacokinetic variables and their correlative relationship to adverse events and clinical outcomes. Results: There was no significant difference in the median DFI or overall survival between the two arms of this trial; the median DFI and survival for standard-of-care (SOC; defined as amputation and carboplatin therapy) dogs was 180 days [95% confidence interval (CI), 144–237] and 282 days (95% CI, 224–383) and for SOC + sirolimus dogs, it was 204 days (95% CI, 157–217) and 280 days (95% CI, 252–332), respectively. Conclusions: In a population of pet dogs nongenomically segmented for predicted mTOR inhibition response, sequentially administered adjuvant sirolimus, although well tolerated when added to a backbone of therapy, did not extend DFI or survival in dogs with appendicular osteosarcoma.

2 July 2022 in Topics in Companion Animal Medicine
Verified
Journal Article
Closed access
ARAlec B. Repasy
Alec B. Repasy
LSLaura E. Selmic
Laura E. Selmic
WKWilliam C. Kisseberth
William C. Kisseberth

1 July 2008 in American Journal of Veterinary Research
Verified
Journal Article
Open access
WKWilliam C. Kisseberth
William C. Kisseberth
SMSridhar Murahari
Sridhar Murahari
CLCheryl A. London
Cheryl A. London
SKSamuel Kulp
Samuel Kulp
CCChing-Shih Chen
Ching-Shih Chen
Objective—To determine whether exposure of canine cancer cells to histone deacetylase (HDAC) inhibitors S(+)-N-hydroxy-4-(3-methyl-2-phenyl-butyrylamino)benzamide (OSU-HDAC42) or suberoylanilide hydroxamic acid (SAHA) results in increased histone acetylation and decreased cell viability and whether any changes in viability involve induction of apoptosis or alterations in progression of the cell cycle. Sample Population—9 canine cancer cell lines. Procedures—Cells from 9 canine cancer cell lines were treated with dimethyl sulfoxide vehicle, OSU-HDAC42, or SAHA, then assays of cell viability were performed. Histone acetylation was assessed by use of western blot analysis. Apoptosis was assessed via ELISA to detect fragmentation of cytoplasmic nucleosomal DNA and western blot analysis to detect cleavage of caspase 3. Cell cycle analysis was performed by use of propidium iodide staining and flow cytometry. Results—Concentrations of OSU-HDAC42 and SAHA required to achieve 50% inhibition of cell viability (IC50) were reached in cells of 6 and 4 canine cancer cell lines, respectively, and ranged from approximately 0.4 to 1.3μM for OSU-HDAC42 and 0.6 to 4.8μM for SAHA. Cells from T-cell lymphoma, mast cell tumor, osteosarcoma, and histiocytic sarcoma lines were most sensitive to HDAC inhibition, with IC50s of < 1μM for OSU-HDAC42 and < 5μM for SAHA. Induction of apoptosis was indicated via cleavage of caspase 3 and increases in cytoplasmic nucleosomes and the subG1 cell population. Conclusions and Clinical Relevance—Micromolar concentrations of HDAC inhibitors OSU-HDAC42 and SAHA induced histone acetylation, cytotoxicity, and apoptosis in canine cancer cells. In general, OSU-HDAC42 was more potent than SAHA.

19 May 2025 in Veterinary and Comparative Oncology
Verified
Journal Article
Open access
MCMichael Childress
Michael Childress
AAAnne Avery
Anne Avery
EBErica Behling‐Kelly
Erica Behling‐Kelly
PBPeter Bennett
Peter Bennett
LBLaura Brockley
Laura Brockley
LALuca Aresu
Luca Aresu
One of the primary objectives of the Oncology Pathology Working Group (OPWG) is for oncologists and pathologists to collaboratively generate consensus documents to standardise aspects of and provide guidelines for oncologic pathology in veterinary species. Consensus is established through critical review of the peer‐reviewed literature relevant to a subgroup's particular focus. In this article, the authors provide a critical review of the current literature regarding methods for the diagnosis and classification of primary nodal lymphomas of dogs, including histopathology, cytopathology, immunophenotyping and assessment of molecular clonality. Knowledge gaps in the current literature and recommendations for future study are also reported. Major conclusions of this consensus include: (1) Histopathology with immunohistochemistry is required for complete diagnosis and classification of nodal lymphomas; (2) Immunohistochemistry and flow cytometry are the most reliable methods of immunophenotyping lymphomas, though neither is clearly superior to the other; (3) Molecular clonality testing should not be used in favour of immunophenotyping assays for classifying lymphomas; and (4) The use of emerging molecular tests for diagnosing lymphomas in the absence of histopathologic, cytopathologic, or immunophenotypic disease characterisation should be restricted to investigational settings until their diagnostic validity and the clinical benefit they confer to patients are more thoroughly characterised. This document represents the opinions of the OPWG and the authors; it does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.

30 May 2023 in Veterinary and Comparative Oncology
Verified
Journal Article
Open access
MSMorgan S. Schrock
Morgan S. Schrock
AZAbigail A. Zalenski
Abigail A. Zalenski
MTMiranda M. Tallman
Miranda M. Tallman
LKLuke Kollin
Luke Kollin
ABAnna Bratasz
Anna Bratasz
MSMatthew Summers
Matthew Summers
High‐grade glioma is an aggressive cancer that occurs naturally in pet dogs. Canine high‐grade glioma (cHGG) is treated with radiation, chemotherapy or surgery, but has no curative treatment. Within the past eight years, there have been advances in our imaging and histopathology standards as well as genetic charactereization of cHGG. However, there are only three cHGG cell lines publicly available, all of which were derived from astrocytoma and established using methods involving expansion of tumour cells in vitro on plastic dishes. In order to provide more clinically relevant cell lines for studying cHGG in vitro, the goal of this study was to establish cHGG patient‐derived lines, whereby cancer cells are expanded in vivo by injecting cells into immunocompromized laboratory mice. The cells are then harvested from mice and used for in vitro studies. This method is the standard in the human field and has been shown to minimize the acquisition of genetic alterations and gene expression changes from the original tumour. Through a multi‐institutional collaboration, we describe our methods for establishing two novel cHGG patient‐derived lines, Boo‐HA and Mo‐HO, from a high‐grade astrocytoma and a high‐grade oligodendroglioma, respectively. We compare our novel lines to G06‐A, J3T‐Bg, and SDT‐3G (traditional cHGG cell lines) in terms of proliferation and sensitivity to radiation. We also perform whole genome sequencing and identify an NF1 truncating mutation in Mo‐HO. We report the characterization and availability of these novel patient‐derived lines for use by the veterinary community.

31 March 2023
Verified
Other
Open access
ALAmy K. LeBlanc
Amy K. LeBlanc
CMChristina N. Mazcko
Christina N. Mazcko
ACAswini Cherukuri
Aswini Cherukuri
EBErika P. Berger
Erika P. Berger
WKWilliam C. Kisseberth
William C. Kisseberth
TFTimothy M. Fan
Timothy M. Fan
Supplementary Fig. 1 depicts the chronology of clinical trial visits and associated procedures for dogs enrolled in this clinical trial.